Latest Insider Transactions at Alnylam Pharmaceuticals, Inc. (ALNY)
This section provides a real-time view of insider transactions for Alnylam Pharmaceuticals, Inc. (ALNY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ALNYLAM PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ALNYLAM PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 29
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,474
-2.06%
|
$1,559,826
$449.02 P/Share
|
|
Aug 19
2025
|
Pushkal Garg EVP Chief R&D |
SELL
Open market or private sale
|
Direct |
1,455
-1.15%
|
$666,390
$458.88 P/Share
|
|
Aug 18
2025
|
Michael W Bonney Director |
SELL
Open market or private sale
|
Direct |
11,250
-40.1%
|
$5,062,500
$450.0 P/Share
|
|
Aug 18
2025
|
Michael W Bonney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+28.62%
|
$787,500
$70.2 P/Share
|
|
Aug 18
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
1,396
-0.74%
|
$630,992
$452.31 P/Share
|
|
Aug 18
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,979
-1.44%
|
$3,154,508
$452.31 P/Share
|
|
Aug 18
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,274
-0.55%
|
$1,027,848
$452.31 P/Share
|
|
Aug 18
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,396
-0.58%
|
$630,992
$452.31 P/Share
|
|
Aug 18
2025
|
Pushkal Garg EVP Chief R&D |
SELL
Open market or private sale
|
Direct |
1,396
-0.77%
|
$630,992
$452.31 P/Share
|
|
Aug 15
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
2,851
+10.57%
|
-
|
|
Aug 15
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,252
+18.4%
|
-
|
|
Aug 15
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,644
+8.14%
|
-
|
|
Aug 15
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,851
+8.46%
|
-
|
|
Aug 15
2025
|
Pushkal Garg EVP Chief R&D |
BUY
Grant, award, or other acquisition
|
Direct |
2,851
+11.0%
|
-
|
|
Aug 14
2025
|
Dennis A Ausiello Director |
SELL
Open market or private sale
|
Direct |
31,448
-25.78%
|
$13,742,776
$437.26 P/Share
|
|
Aug 14
2025
|
Dennis A Ausiello Director |
BUY
Exercise of conversion of derivative security
|
Direct |
31,448
+21.87%
|
$4,497,064
$143.69 P/Share
|
|
Jul 01
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
7,763
+26.74%
|
-
|
|
Jun 02
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,297
-28.28%
|
$5,904,882
$306.0 P/Share
|
|
Jun 02
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,297
+13.04%
|
$2,277,046
$118.59 P/Share
|
|
May 30
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
31,640
-21.4%
|
$9,650,200
$305.0 P/Share
|
|
May 30
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,640
+18.03%
|
$3,733,520
$118.59 P/Share
|
|
May 16
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
8,376
-14.61%
|
-
|
|
May 15
2025
|
Michael W Bonney Director |
SELL
Open market or private sale
|
Direct |
11,250
-3.56%
|
$3,105,000
$276.05 P/Share
|
|
May 15
2025
|
Michael W Bonney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+28.62%
|
$1,473,750
$131.21 P/Share
|
|
May 08
2025
|
Amy W Schulman Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+6.09%
|
-
|
|
May 08
2025
|
Colleen F Reitan Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+50.0%
|
-
|
|
May 08
2025
|
David E I Pyott Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+45.97%
|
-
|
|
May 08
2025
|
Peter N Kellogg Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+50.0%
|
-
|
|
May 08
2025
|
Margaret A Hamburg Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+45.97%
|
-
|
|
May 08
2025
|
Olivier Brandicourt Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+50.0%
|
-
|
|
May 08
2025
|
Michael W Bonney Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+4.41%
|
-
|
|
May 08
2025
|
Dennis A Ausiello Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+45.97%
|
-
|
|
May 08
2025
|
Carolyn R Bertozzi Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+50.0%
|
-
|
|
May 08
2025
|
Charles Elliott Sigal Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+50.0%
|
-
|
|
May 02
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
41,311
-41.88%
|
-
|
|
Apr 16
2025
|
Colleen F Reitan Director |
SELL
Open market or private sale
|
Direct |
36
-100.0%
|
$8,352
$232.86 P/Share
|
|
Mar 24
2025
|
Pushkal Garg EVP Chief R&D |
SELL
Open market or private sale
|
Direct |
5,445
-21.21%
|
$1,633,500
$300.0 P/Share
|
|
Mar 24
2025
|
Pushkal Garg EVP Chief R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
5,445
+17.5%
|
$228,690
$42.22 P/Share
|
|
Mar 24
2025
|
David E I Pyott Director |
SELL
Open market or private sale
|
Direct |
7,440
-98.2%
|
$2,224,560
$299.0 P/Share
|
|
Mar 24
2025
|
David E I Pyott Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,440
+49.55%
|
$654,720
$88.95 P/Share
|
|
Mar 21
2025
|
Pushkal Garg EVP Chief R&D |
SELL
Open market or private sale
|
Direct |
4,321
-17.61%
|
$1,231,485
$285.0 P/Share
|
|
Mar 13
2025
|
Amy W Schulman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+19.73%
|
$360,250
$131.21 P/Share
|
|
Mar 04
2025
|
Pushkal Garg EVP Chief R&D |
SELL
Open market or private sale
|
Direct |
808
-0.81%
|
$194,728
$241.12 P/Share
|
|
Mar 04
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
844
-1.5%
|
$203,404
$241.2 P/Share
|
|
Mar 03
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,877
-0.55%
|
$949,865
$245.33 P/Share
|
|
Mar 03
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,965
+14.91%
|
-
|
|
Mar 03
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,264
-0.37%
|
$309,680
$245.33 P/Share
|
|
Mar 03
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,117
+23.57%
|
-
|
|
Mar 03
2025
|
Pushkal Garg EVP Chief R&D |
SELL
Open market or private sale
|
Direct |
1,749
-0.66%
|
$428,505
$245.04 P/Share
|
|
Mar 03
2025
|
Pushkal Garg EVP Chief R&D |
BUY
Grant, award, or other acquisition
|
Direct |
14,137
+34.28%
|
-
|